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Abstract
Alveolar soft part sarcoma (ASPS) is a rare soft tissue tumor of unknown histogenesis generally characterized by the der(17)
t(X;17)(p11.2;q25) translocation which results in the ASPSCR1-TFE3 gene fusion. Primary ASPS of the thyroid gland has 
not yet been reported. During oncology follow-up for breast cancer, a pulmonary nodule and thyroid gland mass were iden-
tified in a 71-year-old Korean male. Thyroid ultrasound showed a 5.7 cm left thyroid gland mass. After several fine needle 
aspirations, a thyroid gland lobectomy was performed after documenting only non-caseating granulomatous inflammation 
in a biopsy of the lung nodule. A 7.6 cm bulging nodular thyroid gland mass was identified, showing significant destructive 
invasion. Alveolar nests of large polygonal, eosinophilic, granular neoplastic cells were separated by vascularized stroma. 
Colloid was absent. Tumor necrosis and increased mitoses were identified. The neoplastic cells were positive with TFE3 and 
CD68, but negative with pancytokeratin, thyroglobulin, TTF-1, napsin-A, calcitonin, PAX8, CAIX, S100 protein, HMB45, 
SMA, and desmin. FISH confirmed a TFE3 gene rearrangement. The differential includes several primary thyroid gland 
epithelial neoplasms, paraganglioma, PEComa, melanoma, crystal storage disease, and metastatic carcinomas, especially 
Xp11 translocation renal cell carcinoma. The patient has refused additional therapy, but is alive without tumor identified 
(primary or metastatic).
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Introduction
Alveolar soft part sarcoma (ASPS) is a rare sarcoma of 
uncertain histogenesis, accounting for < 1% of soft tis-
sue sarcomas [1]. ASPS is defined by histologically large, 
eosinophilic cells that are arranged in nests or clusters, fre-
quently exhibiting central dyscohesion that yields an alveolar 
appearance, while characterized by a specific translocation 
der(17)t(X;17)(p11.2;q25) that yields the ASPCR1-TFE3 
fusion gene [2]. ASPS is most commonly seen in patients 
aged 15–35 years (median 25 years), with a majority below 
30 years of age [1, 3]. There is a predominance in females, 
although not as well developed in patients > 30 years of age 
[4]. The most common sites of involvement in adults are 
deep soft tissue of the thigh/buttock and trunk [4]. In chil-
dren or infants, the most commons sites of involvement are 
head and neck region, with the orbit and tongue especially 
[5, 6]. Primary ASPS has been reported in almost every ana-
tomic site, including: bone [7], breast [8], female genital 
tract [9], heart [10], larynx [11], liver [12], lung [13], stom-
ach [14], and urinary bladder [15]. However, to the best of 
our knowledge, we herein report the first case of primary 
thyroid gland ASPS. Additionally, we discuss the unique 
differential produced by ASPS presenting as a thyroid gland 
neoplasm and the immunohistochemistry necessary to parse 
ASPS from its histologic mimics.
Case Report
Clinical Presentation
The patient was a 71-year-old Korean male with a past 
medical history significant for breast carcinoma diagnosed 
36 years prior to presentation, managed with surgery only 
(no radiation or chemotherapy). During follow-up imaging 
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studies, a pulmonary nodule was identified, previously fol-
lowed by serial scans. The patient noted mild thyromegaly. 
The patient had a previous thyroid gland ultrasound per-
formed outside the country and was told it was abnormal. A 
repeat thyroid gland ultrasound showed a 5.7 × 4.5 × 4.4 cm 
mass in the left thyroid gland lobe, with Doppler color flow 
demonstrating chaotic/turbulent flow (Fig. 1). On physical 
exam, there was a firm left thyroid gland nodule, which had 
increased in size recently. The patient denied dysphagia, 
odynophagia and hoarseness, although reported a 20 pound 
unintentional weight loss. A thyroid fine needle aspira-
tion (FNA) was performed, and interpreted as Bethesda 
III (atypia of unknown significance). Before further thy-
roid gland evaluation, a computed tomography study was 
performed due to left upper quadrant pain. The study dem-
onstrated both a thyroid gland mass and an 11 mm right 
lower lung lobe nodule. A PET scan demonstrated left hilar 
adenopathy and right lower lobe mass with SUV maximum 
of 17.19, and increased uptake in the left thyroid gland lobe 
mass. No other areas of abnormal hypermetabolic activity 
were detected. A computed tomography guided core needle 
biopsy of the lung demonstrated only non-caseating granu-
lomatous inflammation, with sarcoid considered the most 
likely candidate. Another thyroid gland FNA was performed, 
but was non-diagnostic, which was followed by a third thy-
roid gland FNA, with ThyGeNEXT molecular oncogene 
panel reporting no mutations detected. The Diff-Quik and 
Papanicolaou-stained smears were moderately cellular and 
revealed groups of cohesive cells with abundant granu-
lar eosinophilic cytoplasm and round nuclei. There were 
many “naked” nuclei and clusters arranged around delicate 
endothelium (Fig. 2). Many of the nuclei were unusually 
large (in comparison to uninvolved follicular thyroid epi-
thelium). The cells displayed significant anisocytosis and 
most showed prominent nucleoli (Fig. 2) within nuclei that 
displayed vesicular chromatin. Colloid was inconspicu-
ous, but there was a hemorrhagic and granular background. 
Based on these findings a thyroid gland lobectomy was per-
formed. The diagnosis of ASPS prompted further evaluation 
but failed to identify any soft tissue or organ based primary 
site. Thus, an alternate primary site was not identified. Given 
the presentation of two unusual tumors in an adult patient 
(male breast cancer and adult-onset ASPS), genetic testing 
was offered and is still under consideration at this time. No 
additional surgery was performed for the positive tumor 
margin, and at present the patient has opted to not receive 
radiotherapy or chemotherapy, but is alive without gross dis-
ease at last contact (5 months). 
Pathology
The resected thyroid gland lobectomy weighed 76 g and 
measured 8.7 × 5.4 × 3.7 cm. Gross examination revealed 
a mass that closely approximated the entire volume of the 
lobectomy. Serial sectioning revealed a 7.6 × 5.3 × 3.6 cm 
firm, tan-yellow, and bulging nodular mass.
Histologic examination revealed a widely infiltrative 
and destructive neoplasm that nearly replaced the entire 
lobectomy (Fig. 3). The neoplasm was partially encapsu-
lated, showing significant capsular invasion along with well 
developed and easily identified lymphovascular invasion. 
Direct invasion into the parathyroid gland tissue was also 
observed, with tumor identified on the inked margins of 
Fig. 1  By ultrasound, there was a 5.7 × 4.5 × 4.4 cm mass in the left 
thyroid gland lobe (a), demonstrating chaotic/turbulent flow with 
Doppler color flow (b)
Fig. 2  Fine needle aspiration demonstrated moderate cellularity with 
three-dimensional clusters and single cells in a hemorrhagic and 
granular background (a). Uni- and binucleated tumor cells showed 
abundant delicate cytoplasm eccentrically surrounding large nuclei 
with vesicular chromatin and prominent nucleoli (b)
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resection. The neoplastic cells were arranged in large sheets 
and smaller nests which were separated by thick fibrous con-
nective tissue septae. The nests were divided into alveolar 
spaces and associated with a very richly vascularized stroma 
(Fig. 4). The neoplastic cells were large and polygonal, 
with central round to irregular vesicular nuclei containing 
large, prominent, brightly hypereosinophilic single nucleoli 
(Fig. 4). The nuclei were surrounded by abundant granular to 
eosinophilic cytoplasm, although a few cells had vacuolated 
to cleared cytoplasm. Isolated cells had crystals within the 
cytoplasm that were arranged in aggregates. Retraction arti-
facts were seen in the cytoplasm, which created a dilapidated 
or pseudo-alveolar pattern to the cells (Fig. 4). There were 
easily identified mitotic figures, including atypical forms, 
with 18/2 mm2. Tumor central comedonecrosis was easily 
identified.
With a working diagnosis of alveolar soft part sarcoma, 
several additional studies were performed. A PAS-D high-
lighted PAS positive diastase resistant cytoplasmic rod 
shaped crystals. The neoplastic cells showed strong, diffuse 
nuclear reactivity for TFE3 (Fig. 5), along with CD68. There 
was no reaction in the neoplastic cells for pancytokeratin, 
thyroglobulin (Fig. 5), TTF-1, napsin-A, calcitonin, PAX8 
(Fig. 5), CAIX, S100 protein, SOX10, inhibin, HMB45, 
SMA, synaptophysin, chromogranin, desmin, and calretinin. 
These findings supported a diagnosis of alveolar soft part 
sarcoma. In light of the most unusual presentation clinically 
and by anatomic site of involvement, a TFE3 gene rearrange-
ment was confirmed by FISH (Fig. 6). 
Discussion
ASPS is a tumor that affects predominantly adolescents and 
young adults, and thus considered quite rare in a patient of 
this age and exceptional in the thyroid gland as a primary 
tumor. The tumor is usually slow growing, with a relatively 
high risk (up to 50%) of local recurrence [1], and a high 
delayed metastatic potential, including up to decades after 
the primary tumor has been resected [4, 16]. Therefore, long 
term clinical follow-up with complete, radical surgical exci-
sion is usually recommended, as the overall 5-year survival 
is about 56% [1].
There is a well-known genetic alteration: der(17)t(X;17)
(p11;q25). This translocation results in the fusion of the 
TFE3 transcription factor gene (from Xp11) with the ASP-
SCR1 at 17q25 [2]. Recently, other fusion partners with 
TFE3 have been identified, and include HNRNPH3-TFE3, 
DVL2-TFE3 and PRCC -TFE3 [17], expanding the genetic 
diversity in ASPS, identifying overlap with translocation-
associated renal cell carcinomas and PEComa. The ASP-
SCR1-TFE3 fusion protein localizes to the nucleus and can 
be detected by the immunohistochemical stain TFE3, seen 
irrespective of the fusion partner. TFE3 immunohistochem-
istry is not specific for ASPS, with nuclear expression iden-
tified in a number of neoplasms, including (but not limited 
to): Xp11 translocation renal cell carcinomas [18], PEComas 
[19], granular cell tumors [20, 21], paraganglioma [21, 22], 
solid pseudo-papillary tumors of the pancreas [23], adrenal 
cortical carcinoma [21, 24], and epithelioid hemangioen-
dotheliomas [25]. From these tumors, a subset of renal cell 
Fig. 3  a The neoplasm shows a nodular periphery, surrounded by a 
thin capsule, separating the tumor from the adjacent thyroid gland 
parenchyma. b A nested, alveolar pattern of growth was easily identi-
fied, with prominent vessels between the tumor nests. Colloid was not 
seen, although native thyroid gland was present (top of field)
Fig. 4  a Sheets and nests of cells separated by a richly vascularized 
stroma creating alveolar spaces. b The polygonal neoplastic cells 
were large with a low nuclear to cytoplasmic ratio, with open chro-
matin and single, prominent macronucleoli
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carcinomas and PEComas have the same ASPSCR1-TFE3 
fusion [18, 19, 26].
The morphologic features of this tumor raise a broad dif-
ferential diagnosis within the thyroid gland, including fol-
licular carcinoma (oncocytic type), medullary carcinoma 
(oncocytic type), granular cell tumor, metastatic renal 
cell carcinoma, malignant paraganglioma, PEComa, and 
metastatic melanoma, while a crystal storage disease was 
considered unlikely. A pertinent and targeted discussion 
of the histologic and immunophenotypic characteristics of 
these differential considerations will be set in the context of 
the ASPS diagnosis.
A follicular carcinoma tends to show a follicular pattern 
of growth, although a solid architecture may be seen; shows 
colloid within the follicles; and would express epithelial 
and thyroid linage markers (CK-pan, TTF-1, thyroglobulin, 
PAX8) [27]. Medullary thyroid carcinoma is one of the pri-
mary thyroid gland lesions that is a great mimic, with many 
different architectural patterns and cytologic appearances. 
However, despite overlap, the neoplastic cells would express 
epithelial markers and TTF-1, calcitonin, synaptophysin, 
chromogranin, and PAX8 (variable/weak) [28]. A granular 
cell tumor generally shows a more solid to packeted architec-
ture, while generally lacking invasion (although malignant 
granular cell tumors of the thyroid gland are recognized); the 
cytoplasm would be granular and eosinophilic in appearance 
and would express a combination of S100 protein, SOX10, 
inhibin, and CD68 [29]. The lack of epithelial marker reac-
tivity argues against metastatic renal cell carcinoma, how-
ever the Xp11 translocation renal cell carcinomas usually 
underexpress epithelial markers, but they uniformly express 
positivity for PAX8 [30]. Interestingly, ASPSCR1-TFE3 
renal cell carcinomas typically present with metastases and 
are known to metastasize 20–30 years after diagnosis, much 
like ASPS [18]. The absence of a PAX8 staining, renal mass, 
or history of renal cell carcinoma argues for an alternative 
diagnosis. Head and neck paraganglioma, and especially 
Fig. 5  Immunohistochemistry 
studies to exclude thyroid origin 
as well as prove the histologic 
diagnosis included negative a 
thyroglobulin, b pancytokeratin 
AE1/AE3, and c PAX8, while 
the neoplastic cells showed a 
strong and diffuse TFE3 nuclear 
reaction (d)
Fig. 6  A FISH breakapart was employed to document spatial sepa-
ration of the green (3′TFE3) and red (5′TFE3) signals, supporting a 
Xp11.23 rearrangement (yellow signals are intact green/red fusion; 
the translocation partner is not documented)
705Head and Neck Pathology (2020) 14:701–706 
1 3
those within the thyroid gland, are all considered to be 
malignant by definition, although now classified by a risk 
stratification approach. There is a smaller nest size (zellbal-
len), with isolated pleomorphic cells usually easily identi-
fied; mitoses are usually inconspicuous; the neoplastic cells 
may express TFE3, but show chromogranin, synaptophysin, 
and SDHB (the latter may be present or absent depending 
on possible mutation status, but is positive in most cases), 
with S100 protein positive sustentacular cells, the latter 
lacking in ASPS [22, 31]. A perivascular epithelioid cell 
tumor (PEComa) is a mesenchymal epithelioid neoplasm 
often associated with blood vessel walls and usually showing 
myomelanotic differentiation with HMB45 (most sensitive) 
and smooth muscle actin [32], although not yet documented 
as a primary tumor in the thyroid gland. Primary thyroid 
gland melanoma is not reported, but metastatic melanoma 
to the thyroid gland may show morphologic overlap with 
ASPS. Melanoma typically shows large polygonal cells 
that are nested, but not really in a specific pattern, while 
frequently showing cytoplasmic melanin pigment, promi-
nent nucleoli and intranuclear cytoplasmic inclusions; the 
neoplastic cells typically express S100 protein, SOX10, 
HMB45, and Melan-A among other markers [33]. In this 
patient, the lack of melanoma history argues against such 
a lesion. Crystal storage disease usually has an increased 
number of lymphocytes and inflammatory cells, with the 
histiocytes stuffed with crystals, while showing a strong 
and diffuse CD68 immunoreactivity [34]; the current case 
failed to show any significant inflammatory cells. Rhabdo-
myomas and alveolar rhabdomyosarcoma were considered, 
but the age of the patient along with the tumor site militated 
against such a consideration, further supported by a lack of 
muscle marker immunoexpression [35, 36]. The patient’s 
known lung lesion was considered, but demonstrated only 
non-caseating granulomatous inflammation rather than met-
astatic disease, or as a source of a primary lesion. Given the 
very vascular nature of the thyroid gland, a metastatic tumor 
to the thyroid gland must be considered. It is well known that 
renal cell carcinomas can present with a large single, encap-
sulated tumor nodule in the thyroid gland [37], and so the 
presentation of a large, single mass would not preclude the 
possibility of a metastatic tumor. However, during careful 
evaluation by imaging studies, no primary tumor has been 
identified anywhere else, and thus a primary thyroid gland 
ASPS can be diagnosed.
The major negative prognostic factors influencing 
overall outcome are older patient age at presentation, 
tumors > 10 cm, primary trunk location and metastases at 
presentation. Thus, no histologic features were prognosti-
cally significant in this patient [16]. The 5-year disease free 
survival for localized disease and those that present with 
metastases is 71% and 20%, respectively [4]. This patient 
showed a microscopic positive tumor margin, but additional 
surgery was not accepted and no additional therapy has 
been performed at this time. Long term follow-up is recom-
mended in light of the significant risk of delayed metastases. 
Our patient is currently disease free, but will require essen-
tially lifelong follow-up, due to the risk of delayed metas-
tases. Clinical management will evolve as more cases are 
reported.
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